Kitano Atsuko, Ono Makiko, Yoshida Masayuki, Noguchi Emi, Shimomura Akihiko, Shimoi Tatsunori, Kodaira Makoto, Yunokawa Mayu, Yonemori Kan, Shimizu Chikako, Kinoshita Takayuki, Fujiwara Yasuhiro, Tsuda Hitoshi, Tamura Kenji
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Department of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan.
ESMO Open. 2017 May 2;2(2):e000150. doi: 10.1136/esmoopen-2016-000150. eCollection 2017.
The presence of tumour-infiltrating lymphocytes (TILs) is a favourable prognostic factor in patients with early breast cancer. Programmed cell death-1 (PD-1) and its ligand PD-L1 are associated with a variety of adverse features. The purpose of this study was to clarify the relationships between TILs, PD-1 and PD-L1 as well as their prognostic implications in early breast cancer.
We investigated 180 patients with breast cancer who received neoadjuvant chemotherapy and underwent subsequent surgery for stage II-III invasive breast carcinoma between 1999 and 2007. TIL expression was classified as low or high using a previously reported scoring model. PD-1 and PD-L1 expression levels were determined by immunohistochemistry. The correlation between PD-1 expression in TILs and PD-L1 expression in cancer cells was also investigated.
Higher tumour grade was significantly correlated with PD-L1 expression in tumours (p<0.0001). PD-1 and PD-L1 expression levels were associated with tumour subtype and were highest in triple-negative tumours (p<0.0001). Furthermore, expression of each of PD-1 and PD-L1 was significantly correlated with higher TIL expression and pathological complete response (pCR) (p<0.0001). PD-L1 expression in cancer cells was significantly correlated with PD-1 expression in TILs (p=0.03). The correlations between pCR and expression of each of PD-L1 and PD-1 were not significant.
Expression of PD-L1 and PD-1 in early breast cancer is associated with higher TIL scores and pCR; conversely, expression of these proteins correlates with poor prognostic clinicopathological factors such as tumour grade and subtype. TILs, PD-1 and PD-L1 can potentially predict the response to treatment.
肿瘤浸润淋巴细胞(TILs)的存在是早期乳腺癌患者的一个有利预后因素。程序性细胞死亡蛋白1(PD-1)及其配体PD-L1与多种不良特征相关。本研究的目的是阐明TILs、PD-1和PD-L1之间的关系及其在早期乳腺癌中的预后意义。
我们调查了1999年至2007年间接受新辅助化疗并随后接受II-III期浸润性乳腺癌手术的180例乳腺癌患者。使用先前报道的评分模型将TIL表达分为低或高。通过免疫组织化学测定PD-1和PD-L1的表达水平。还研究了TILs中PD-1表达与癌细胞中PD-L1表达之间的相关性。
更高的肿瘤分级与肿瘤中PD-L1表达显著相关(p<0.0001)。PD-1和PD-L1表达水平与肿瘤亚型相关,在三阴性肿瘤中最高(p<0.0001)。此外,PD-1和PD-L1各自的表达与更高的TIL表达和病理完全缓解(pCR)显著相关(p<0.0001)。癌细胞中PD-L1表达与TILs中PD-1表达显著相关(p=0.03)。pCR与PD-L1和PD-1各自表达之间的相关性不显著。
早期乳腺癌中PD-L1和PD-1的表达与更高的TIL评分和pCR相关;相反,这些蛋白的表达与不良预后的临床病理因素如肿瘤分级和亚型相关。TILs、PD-1和PD-L1可能预测治疗反应。